- Published at
- by seekingalpha.com
neutral
neutral
Celyad Oncology SA GAAP EPS of -€0.14, revenue of €0.2M
Celyad Oncology reports FY GAAP EPS of -$0.14 and revenue growth of 100% Y/Y to $0.2M.
News for Celyad Oncology SA (CYAD)
- Published at
- by globenewswire.com
mixedmixedIDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight
The IDH inhibitors market is expected to grow significantly in the coming years. This is due to the rising occurrence of IDH-mutated cancers, such as acute...- Published at
- by marketscreener.com
positivepositiveCelyad Oncology : Report of the Statutory Auditor on the Consolidated Annual Account 2023 ENG -April 05, 2024 at 01:11 am EDT
T : +32 3 230 58 40 Uitbreidingstraat 72/1 ...- Published at
- by seekingalpha.com
neutralneutralCelyad Oncology SA reports FY results (OTCMKTS:CLYYF)
Celyad Oncology reports FY2023 revenue of €0.1M and a net loss of €8.5 million, reflecting challenging financial performance in the oncology sector.- Published at
- by investing.com
positivepositiveCelyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights By Investing.com
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights- Published at
- by valueandopportunity.com
mixedmixedAll Belgian Shares Part 4 – Nr. 61-80
And on we go, turning rocks and kissing frogs in the Belgian stock market. This batch of 20 randomly selected stocks yielded 4 watch list candidates, among them a stock I owned in the past. So far, the "Expert Market" is a littlebit disappointing. For many of the companies there it is really hard to…- Published at
- by gurufocus.com
positivepositiveHalf Year 2023 Celyad Oncology SA Earnings Call Transcript
Sep 05, 2023 / 11:00AM GMTOperator Greetings. Welcome to Celyad Oncology's half-year 2023 earnings conference call. (Operator Instructions) Please note that thi- Published at
- by gurufocus.com
positivepositiveQ4 2022 Celyad Oncology SA Earnings Call Transcript
Mar 24, 2023 / 12:00PM GMTOperator Greetings. Welcome to the Celyad Oncology full-year 2022 earnings conference call. (Operator Instructions) Please note that t- Published at
- by gurufocus.com
positivepositiveQ4 2021 Celyad Oncology SA Earnings Call Transcript
Mar 25, 2022 / 12:00PM GMTOperator Welcome to the Celyad Oncology second half 2021 earnings conference call. (Operator Instructions) Please note this event is b- Published at
- by gurufocus.com
positivepositiveQ2 2022 Celyad Oncology SA Earnings Call Transcript
Aug 05, 2022 / 12:00PM GMTOperator Greetings and welcome to the Celyad Oncology first half 2022 financial results. (Operator Instructions) As a reminder, this c- Published at
- by gurufocus.com
positivepositiveQ2 2021 Celyad Oncology SA Earnings Call Transcript
Aug 04, 2021 / 12:00PM GMTOperator Good morning, and welcome to the Celyad Oncology first-half 2021 earnings conference call. (Operator Instructions) Please not- Published at
- by marketscreener.com
mixedmixedImmunoPrecise Antibodies : 2023 Notice of Meeting & Information Circular -October 18, 2023 at 03:00 pm EDT
IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF...- Published at
- by prnewswire.com
mixedmixedCell Therapy Market to grow by USD 31.04 billion from 2022 to 2027 | Proven effectiveness of CAR T-cell therapy boosts the market - Technavio
/PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress...- Published at
- by globenewswire.com
mixedmixedGlobal CAR T-Cell Therapy Market Size on a Meteoric Rise: Envisioning $2406.39 Million by 2030 with a Striking CAGR of 26.20%
[222 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global CAR T-Cell Therapy Market size &...- Published at
- by prnewswire.com
mixedmixedCAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
/PRNewswire/ -- The CAR T-cell therapy market is expected to grow by USD 1,999 million from 2022 to 2027, progressing at a CAGR of 13.44% as per the latest...- Published at
- by globenewswire.com
mixedmixedAcute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli
The acute myeloid leukemia market has a promising outlook with emerging therapies. The overall dynamics of the acute myeloid leukemia market are...- Published at
- by globenewswire.com
mixedmixedDelisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Gre
NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the ordinary shares of Puhui Wealth Investment...- Published at
- by wolfstreet.com
mixedmixedThe 1001 Imploded Stocks of 2022 (Down 80% or More)… So Far
The massacre, stock by stock, all 1001 of them, listed right here.UPHTPSTTLRYTALN.MXTALNGLNEGGMAPSLTRPAIDWDPROCRDLCGRNBWMXBTXBTCMBLDEBKSYBEEMWBEEMBBLGZEPPXYFXINVJETVIOTVHCSVFDSTGSNMPSANWQRTEAPWPALIPACKOBSVN.MXOBSVOBSN.SWNVIVNUWENRXPNKTRMYMDMVSTMTLSN.MXMTLSMPSYFMOR.DEMORMNTSMMATMIGIMDJHLKCOLFMDKXINWKXINKPLTIBRXGXE.DEGLPGFGLPG.ASGLPGFNHCEVGN.TAEVGNERYP.PAERYPENSCELYS.NECYADCVNACOECMVLFCLLSCELUAVTXAUIDATYATXSATTOALCLS.PAAGILADXN.SWADXNADDXFAACG0UNL.L0QSS.L0QNV.L0QFK.L0A79.LVYNTSTABGRBXGBOXFWPCANF.TACANFATERASXCAPZ.AX- Published at
- by benzinga.com
mixedmixed71 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.ZLDPFZEALWBAIVVPRVIEWWVIEWTRKATGISXTCSIGAOTRAWOTRAUOTRANURONOVNNNVCNNOXMNROMKDKOD.MXKODIMACWIMACHGENELOXEBSDDOG.MXDDOGD1DG34.SACYADCPOPCNFRCMVLFCMRXCLLSBTCYBTCMBLNDBILLBBIGAUUDWAUUDALCLS.PAAFI0QFK.L0IGA.L0A75.L0A4P.LUAAC.MXUAA.MXUAAUAU9RA.DEU9R.DEU2ST34.SAU1AI34.SAU.MXUTCRXSYP.DESTAFSNPSSLRXNMTCDNMTCMFHKDNYIMNMEOSEWEOSEACRX0R2I.L0LIK.L0LBP.LSPTHOG.MXHOGHAR.DEH1OG34.SAGDSN.MXGDSG1DS34.SADPSICSCO.MXCSCOCIS.DECIS.BRBBWI.MXBBWIB1BW34.SA9698.HK4333.HK0QYY.L- Published at
- by benzinga.com
mixedmixedStocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market ...